Roundup

Five things for pharma marketers to know: Friday, January 27, 2023

Jack O'Brien

January 27, 2023

5:00 am

Congress eyes PBMs; Abzena lays off 80; Concentra builds financial penalties into contract clauses to discourage workers from leaving.

Five things for pharma marketers to know: Thursday, January 26, 2023

Lecia Bushak

January 26, 2023

5:00 am

Merck stops Keytruda trial for prostate cancer; Pharma CEOs doubt Mark Cuban’s efforts to upend drug industry; Novartis fined $2.8 million by Belgian antitrust regulators over Lucentis.

Five things for pharma marketers to know: Wednesday, January 25, 2023

Lecia Bushak

January 25, 2023

5:00 am

FDA to hold an expert panel to define the process for updating COVID-19 vaccines annually; Finch Therapeutics halts Phase III trial for stool-in-a-capsule treatment, lays off most staff; Long COVID is keeping a significant number of people out of work.

Five things for pharma marketers to know: Tuesday, January 24, 2023

Jack O'Brien

January 24, 2023

5:00 am

Rezo Therapeutics seizes JPM spotlight to advance mission; Veeva Systems’ stock is a buy; “Pharma Bro” Martin Shkreli is in the FTC’s crosshairs again

Five things for pharma marketers to know: Monday, January 23, 2023

Jack O'Brien

January 23, 2023

5:00 am

Sinopharm’s biotech unit receives approval for clinical trials of mRNA COVID vaccine; Prosecutors argue Elizabeth Holmes should be in prison, not luxurious estate; Former President Trump allegedly told former Secretary of State Mike Pompeo to ‘shut the hell up’ about China.

Five things for pharma marketers to know: Friday, January 20, 2023

Jack O'Brien

January 20, 2023

5:00 am

Novartis CEO says COVID-19 will likely become endemic; WashPo calls on Congress to act on drug-resistant antibiotics; Ex-Google comms chief D-J Collins founds biotech startup Early.

Five things for pharma marketers to know: Thursday, January 19, 2023

Jack O'Brien

January 19, 2023

5:00 am

Moderna CEO says company is in active discussions with China about vaccines; Wilbur Ross’ SPAC plans to take Aprinoia public; Former Biogen CEO says company ‘shot themselves in the foot’ with Aduhelm pricing.

Five things for pharma marketers to know: Tuesday, January 17, 2023

Lecia Bushak

January 17, 2023

5:00 am

Roche-backed startup Arch Oncology drops anti-CD47 antibody and lays off entire staff; Researchers posit that aging is a reversible process based on experiments in mice; TikTok star says stopping Ozempic made her binge eating worse.

Five things for pharma marketers to know: Friday, January 13, 2023

Jack O'Brien

January 13, 2023

5:00 am

Routine vaccinations drop among kindergartners for third consecutive year; Cancer death rate falls 33% since 1991; Sanofi provides VC arm with $750 million capital commitment.

Five things for pharma marketers to know: Thursday, January 12, 2023

Lecia Bushak

January 12, 2023

5:00 am

Buffalo Bills player Damar Hamlin is discharged from a Buffalo hospital; FDA approves AstraZeneca and Avillion’s asthma rescue treatment Airsupra in adults; Element Biosciences announces $200 cost of human genome sequencing.

Five things for pharma marketers to know: Wednesday, January 11, 2023

Jack O'Brien

January 11, 2023

5:00 am

The White House eyes an end to the emergency designation for COVID-19 as soon as this spring; The Biden administration weighs a ban on gas stoves citing links to asthma, respiratory issues; AbbVie and Anima Biotech plan to collaborate on mRNA biology modulators.

Five things for pharma marketers to know: Tuesday, January 10, 2023

Lecia Bushak

January 10, 2023

5:00 am

Ipsen buys Albireo Pharma for $952 million; Supreme Court rebuffs Pfizer’s plan to help patients pay for heart medication; Teva says 48 states agree to its $4.25 billion opioid settlement.

Five things for pharma marketers to know: Monday, January 9, 2023

Lecia Bushak

January 9, 2023

5:00 am

Pfizer discusses license for generic Paxlovid treatment with China; AbbVie spends $30 million upfront for Immunome partnership to bolster antibody research; Amgen agrees to spend as much as $2 billion in Synaffix ADC licensing deal.

Five things for pharma marketers to know: Friday, January 6, 2023

Jack O'Brien

January 6, 2023

5:00 am

Damar Hamlin is awake and neurologically intact, agent says; Sen. Bob Casey announces he has prostate cancer; Johnson & Johnson files for IPO of Kenvue.

Five things for pharma marketers to know: Thursday, January 5, 2023

Lecia Bushak

January 5, 2023

5:00 am

Eli Lilly strikes $55 million deal with Capsida Biotherapeutics to develop gene therapies; Geron’s experimental drug for rare blood cancers shows efficacy; Justice Departments gives U.S. Postal Service go-ahead to mail abortion medication to states restricting the procedure.